Pancreatic cancer musters HER2 signaling through DUSP6 to circumvent therapeutic MAPK inhibition.

被引：0
|
作者：
Bulle, Ashenafi Shiferaw [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1086
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pancreatic cancer enhances HER2 signaling through DUSP6 to circumvent therapeutic MAPK inhibition.
    Bulle, Ashenafi Shiferaw
    Seehar, Kuljeet
    Bansod, Sapana
    Chen, Yali
    Hung-Po, Chen
    Dodhiawala, Paarth B.
    Li, Lin
    Somani, Vikas
    Mudd, Jacqueline
    Fields, Ryan C.
    Knoerzer, Deborah
    Wang-Gillam, Andrea
    Kian-Huat, Lim
    CANCER RESEARCH, 2022, 82 (12)
  • [2] BOP1 Promotes Prostate Cancer through the DUSP6/MAPK Pathway
    Wu, Xiaoqing
    Jing, Zheng
    Huang, Tianpu
    Jing, Yongsheng
    ARCHIVOS ESPANOLES DE UROLOGIA, 2023, 76 (06): : 445 - 453
  • [3] DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+breast cancer
    Momeny, Majid
    Tienhaara, Mari
    Sharma, Mukund
    Chakroborty, Deepankar
    Varjus, Roosa
    Takala, Iina
    Merisaari, Joni
    Padzik, Artur
    Vogt, Andreas
    Paatero, Ilkka
    Elenius, Klaus
    Laajala, Teemu D.
    Kurppa, Kari J.
    Westermarck, Jukka
    EMBO MOLECULAR MEDICINE, 2024, 16 (07) : 1603 - 1629
  • [4] Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
    Marin, Arnaldo
    Al Mamun, Abdullah
    Patel, Hima
    Akamatsu, Hiroaki
    Ye, Dan
    Sudhan, Dhivya R.
    Eli, Lisa
    Marcelain, Katherine
    Brown, Benjamin P.
    Meiler, Jens
    Arteaga, Carlos L.
    Hanker, Ariella B.
    CANCER RESEARCH, 2023, 83 (18) : 3145 - 3158
  • [5] EGFR and HER2 inhibition in pancreatic cancer
    Naomi Walsh
    Susan Kennedy
    AnneMarie Larkin
    Brendan Corkery
    Lorraine O’Driscoll
    Martin Clynes
    John Crown
    Norma O’Donovan
    Investigational New Drugs, 2013, 31 : 558 - 566
  • [6] EGFR and HER2 inhibition in pancreatic cancer
    Walsh, Naomi
    Kennedy, Susan
    Larkin, AnneMarie
    Corkery, Brendan
    O'Driscoll, Lorraine
    Clynes, Martin
    Crown, John
    O'Donovan, Norma
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 558 - 566
  • [7] A HER3/DUSP6 loop determines sensitivity to HER2-targeted therapies in breast cancer
    Momeny, M.
    Merisaari, J.
    Padzik, A.
    Tienhaara, M.
    Aspelin, W.
    Westermarck, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1093 - S1093
  • [8] Soyasaponin Ag inhibits triple-negative breast cancer progression via targeting the DUSP6/MAPK signaling
    Huang, Shoucheng
    Huang, Ping
    Wu, Huazhang
    Wang, Song
    Liu, Guodong
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2021, 59 (04) : 291 - 301
  • [9] Upregulation of fibroblast growth factor 2 contributes to endometriosis through SPRYs/DUSP6/ERK signaling pathway
    Yu, Xiaoyan
    Wang, Yuping
    Tan, Xiaowei
    Li, Mingjiang
    ACTA HISTOCHEMICA, 2021, 123 (05)
  • [10] A positive feedback loop of ARF6 activates ERK1/2 signaling pathway via DUSP6 silencing to promote pancreatic cancer progression
    Xiao, Bingkai
    Zhang, Yue
    Lu, Zekun
    Chen, Weibo
    An, Yong
    Zu, Guangchen
    Xu, Xiaowu
    Wu, Di
    Yang, Hao
    Qin, Yi
    Chen, Xuemin
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2022, 54 (10) : 1431 - 1440
12345